CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

belapectin

Small moleculeexperimental

Clinical trial activity

9 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
4
Phase 3
1
Phase 4
0

Earliest trial started Jul 1, 2013 (NCT01899859)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gr-md-02

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04987996Phase 2Jan 1, 2022Providence Health & Services
NCT04365868Phase 2/Phase 3 (Phase 3)Jun 30, 2020Galectin Therapeutics Inc.
NCT04332432Phase 1Apr 30, 2020Galectin Therapeutics Inc.
NCT02575404Phase 1Oct 1, 2015Galectin Therapeutics Inc., Providence Health & Services
NCT02407041Phase 2Sep 1, 2015Galectin Therapeutics Inc.
NCT02421094Phase 2Sep 1, 2015Galectin Therapeutics Inc.
NCT02462967Phase 2Jun 1, 2015Galectin Therapeutics Inc., Indiana University, United States Army
NCT02117362Phase 1Mar 1, 2014Galectin Therapeutics Inc., Providence Health & Services
NCT01899859Phase 1Jul 1, 2013Emory University, Galectin Therapeutics Inc., Icahn School of Medicine at Mount Sinai, Indiana University, St. Louis University, United States Army, Virginia Commonwealth University
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Galectin Therapeutics Inc.For profit8632013
Providence Health & ServicesAcademic/Hospital3322014
Indiana UniversityAcademic/Hospital2022013
United States ArmyGovernment2022013
Emory UniversityAcademic/Hospital1012013
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012013
St. Louis UniversityAcademic/Hospital1012013
Virginia Commonwealth UniversityAcademic/Hospital1012013
8 organizations
Page 1 / 1